Abstract
Toxicology tests that rely on human cells and tissues instead of animals are rapidly evolving, driven by widespread interest in reducing the cost and stigma associated with animal testing and the desire to test large numbers of chemicals rapidly. Now, tobacco firms are joining pharmaceutical, pesticide, and chemical manufacturers in investing heavily in the technology. Big tobacco is making more appearances at scientific conferences focused on nonanimal toxicology testing. Representatives from tobacco giants—British American Tobacco, Japan Tobacco, Philip Morris International, and Reynolds American—participated in the annual meeting of the American Society for Cellular & Computational Toxicology (ASCCT) in September. Their ultimate goal: to convince officials at the U.S. Food & Drug Administration’s Center for Tobacco Products (CTP) that in vitro methods for predicting respiratory toxicology in humans are ready for prime time. The industry is facing increased testing requirements for e-cigarettes and othe...
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
